麻豆传媒

---

---

Dr. Pongas is a board certified hematologist and oncologist with clinical experience in indolent and aggressive lymphomas. His research interest is the development of cancer therapeutics for B cell lymphomas and viral associated lymphomas. He has done significant laboratory work in Diffuse Large B cell lymphoma elucidating the therapeutic role of inhibiting various PI3K isoforms. He collaborates with clinical scientists to develop novel therapies in lymphomas and with laboratory scientists to study the mechanism of resistance to the therapies and ways to bypass it. With this approach he hopes to develop combinational therapies and increase the cure rates of various lymphomas.

Jonathan C. Trent, MD, PhD, is professor of medicine, associate director for clinical research, and director of the Bone and Soft-tissue Sarcoma Group at the Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL. He earned his undergraduate degree in chemistry at Southeastern Oklahoma State University and his MD and PhD in cancer biology from The University of Texas Health Science Center. He completed an internship and residency in internal medicine at The University of Texas Health Science Center and a fellowship in medical oncology at The University of Texas MD Anderson Cancer Center while serving as chief fellow. Prior to joining the University of Miami Miller, he held appointments as faculty of The University of Texas Graduate School of Biomedical Sciences at Houston and associate professor of medicine in the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston.

Dr. Merchan is a tenured Professor of Medicine in the division of Medical Oncology. He is the Co-leader of the Translational and Clinical Oncology Research Program, the Director of the Phase 1 Clinical Trials Program, and the Associate Director of the NIH funded Calabresi Clinical Oncology Research Career Development Award. As a physician scientist, his contributions to science include redefining the role of the plasminogen activator system in cancer progression, the development of novel preclinical and clinical strategies to overcome resistance in RCC and angiogenesis dependent cancers, and the preclinical and clinical development of tumor and stromal targeted oncolytic viruses and virus-drug combinations. He leads the only academic phase I program in South Florida, bringing novel treatment strategies to many patients with advanced cancer. Dr. Merchan has an established track record in translational cancer research, bringing lab discoveries to the clinic, and has been involved in the development of novel, effective treatment strategies in genitourinary cancers, which resulted in practice changing publications and introduced new treatment options for cancer patients.

Dr. Andrei Nikiforchin is a dedicated surgical oncologist, who graduated from the First Pavlov State Medical University in St. Petersburg, Russia, and further trained across Europe and the United States. He has distinguished himself in various roles, including a Clinical Researcher in Surgical Oncology at Mercy Medical Center in Baltimore, MD, a Medical Writer and Editor at "OncoWiki", and an Expert Consultant at "Prosto Sprosit'". Renowned for his surgical expertise and significant contributions to oncology research, Dr. Nikiforchin has authored multiple peer-reviewed publications. His experience is further amplified by his active participation in various professional consortiums and societies, commitment to community-oriented initiatives, and proficiency in English, Ukrainian, and Russian.
Andrei Nikiforchin, M.D., is a GCP-certified researcher in the Surgical Oncology Department of The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland, USA. He received his medical doctor degree at Pavlov First State Medical University in St. Petersburg, Russia, in 2015, and then got two specialties in general surgery and surgical oncology. In 2018 after finishing his work in Clinical Hospital #1 MEDSI in Moscow, Russia, Dr. Nikiforchin moved to the United States and started research at The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland. His areas of interest and investigation include gastrointestinal and neuroendocrine tumors, peritoneal surface malignancies, and cytoreductive surgery. Dr. Andrei Nikiforchin is a member of ASCO and SSO since 2019 and RUSSCO since 2021.

Dr. Panayotis Ledakis is an oncologist in Baltimore, Maryland and is affiliated with multiple hospitals in the area, including  and . He received his medical degree from University of Athens and has been in practice for more than 20 years. Dr. Panayotis Ledakis has expertise in treating lymphoma, small intestine/colorectal cancer, prostate cancer, among other conditions - see all areas of . Dr. Panayotis Ledakis accepts Medicare, Aetna, Cigna, United Healthcare - see other . Dr. Panayotis Ledakis is highly recommended by patients.

I graduated from the Government Medical College, Trivandrum, India and then completed my Internal Medicine residency at the University of Arkansas for Medical Sciences, Little Rock.
I am interested in solid tumors with a focus on clinical research in breast cancer, genitourinary malignancies, and neuroendocrine tumors.
My goal is to become an academic physician and lead a research-focused career. Interesting Facts: I am trained in Indian classical dancing, and I love gardening.
I am a hematology and oncology fellow at the Roswell Park Comprehensive Cancer Center. I am actively involved in clinical research in oncology and medicine. My main interest is solid tumor malignancies with a focus on breast cancer and genitourinary malignancies. I am interested in health outcomes research, quality of life, immunotherapy and targeted agents, tumor microenvironment studies, and the development of newer therapeutics.

Bailey Loving, originally from Denver, Colorado, embarked on his academic journey in molecular biology at The University of Denver, where he developed an early interest in radiation biology. He then completed his medical doctorate at the University of Colorado, where he further pursued his interest in oncology. Currently training at Beaumont, Bailey is dedicated to enhancing his skills in using diverse radiation modalities for complex cases and is keen on integrating basic science research with clinical applications. Outside of his professional endeavors, he enjoys wildlife photography, canoeing in the Great Lakes, spending time with his fiancé, playing the piano, playing video games, and continually learning new things. Additionally, Bailey takes pleasure in coding, wildlife photography (Instagram @drlovingphotography), playing with his mini Goldendoodle, Guinea, and playing ping pong.

Shipra Gandhi, MD is an Assistant professor of oncology at the Roswell Park Comprehensive Cancer Center. She completed her fellowship in hematology and oncology at Roswell Park Comprehensive Cancer Center, Buffalo, NY and recieved her board certification from the American Board of Internal Medicine.
For medical oncologist and researcher , Assistant Professor of Oncology specializing in breast cancer in the Department of Medicine at Roswell Park Comprehensive Cancer Center, the path to physician-scientist was clear from the very beginning.
“I was raised in a family of physicians. Both my parents are doctors, and I grew up listening to their conversations about managing difficult cases, so I was very interested in the field of medicine from an early age,” says Dr. Gandhi, who was born and raised in India. Dr. Gandhi attended the prestigious Lady Hardinge Medical College in New Delhi and worked on a project funded by the Indian Council of Medical Research that investigated advanced methods of tuberculosis detection. “I knew from the very beginning that I wanted to become a doctor. But I was also interested in new discoveries, so I knew that in addition to taking care of patients, I somehow wanted to be actively involved in research to move the field forward.”

---

---

---

Dr. Holly Pederson is the Director of the Medical Breast Program at the Cleveland Clinic and Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. She runs a Hereditary High Risk Clinic for patients with identified genetic mutations predisposing to breast and is actively involved in clinical research. She is Board Certified in Internal Medicine, completed a clinical genetics fellowship at Cleveland Clinic in 2008 and the City of Hope Intensive Course in Cancer Risk Assessment in 2017. She serves on the NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian committee. She received her undergraduate degree in biochemistry from the University of California at Santa Barbara and completed medical school and her internal medicine residency at the University of California, San Francisco where she earned the distinction of Alpha Omega Alpha. Dr. Pederson emphasizes wellness and prevention in her personal and professional endeavors and would like to be part of a national movement as part of Breastcancer.org that emphasizes breast health, women's health, and overall health.

Dr. Gupta is a genitourinary oncologist with a research focus on clinical and translational research in genitourinary cancers. Prior to joining the Cleveland Clinic in June 2019, Dr. Gupta was an associate professor at the University of Minnesota where she led the phase I interdisciplinary Solid Tumor Program and Genitourinary Oncology Research. 



Research Information

Research Interests

Dr. Gupta has expertise and interest in novel targeted therapy and immunotherapy trials across genitourinary cancers. She has led several early and late-phase clinical trials including investigator-initiated trials with novel combinations in bladder cancer and testicular cancer, for example, neoadjuvant use of nivolumab and platinum doublet in muscle-invasive bladder cancer, enzalutamide and platinum-doublet in metastatic androgen receptor-positive bladder cancer, brentuximab and bevacizumab in CD30+ germ cell tumors. In collaboration with her basic science colleagues including Dr. Scott Dehm at University of Minnesota, she is studying the molecular efficacy of enzalutamide.
Dr. Gupta is also interested in understanding the resistance mechanisms to anti-PD-1/PD-L1 therapies and serves as a member of the Society for Immunotherapy of Cancer Anti-PD-1/PD-L1 resistance taskforce. She has also been appointed to serve as a member on the annual scientific committee for non-prostate cancers.

---

Dr. Sagus Sampath is a radiation oncologist in Duarte, California and is affiliated with multiple hospitals in the area, including  and . He received his medical degree from University of California, Irvine, School of Medicine and has been in practice between 11-20 years. Dr. Sagus Sampath accepts Medicare, Blue Cross, United Healthcare - see other .

Sawsan Rashdan, M.D., is an Assistant Professor in the  at UT Southwestern Medical Center. She specializes in treating thoracic malignancies. She is the Director of Thoracic Medical Oncology Clinical Operations.
Dr. Rashdan earned her medical degree at the Faculty of Medicine of Damascus University in Syria. She performed her residency in internal medicine at the Indiana University School of Medicine, where she also completed advanced fellowship training in hematology and oncology.
Certified by the American Board of Internal Medicine in hematology and medical oncology, she joined the UT Southwestern faculty in 2016.
Dr. Rashdan’s research focuses on lung cancer, and she has published a number of academic articles on the subject. She has received funding to pilot a clinical trial to investigate the role of stereotactic ablative radiotherapy (SABR) plus osimertinib as first-line treatment in epidermal growth factor receptor-mutated non-small cell lung cancer. Additionally, she is the Division Quality Officer as well as the Director of Health Equity in the division of hematology and oncology, leading the effort to reduce inequities of health care and increase access of cancer prevention education in minority groups.
Dr. Rashdan also spends time teaching the trainees at UTSW, she leads the lung cancer curriculum for the hematology and oncology fellows at Parkland. In addition to mentoring many fellows, residents, and medical students.
She is a member of several professional organizations, including the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Dallas County Medical Society as well as American Muslim Women Physicians Association. She is also a member of several committees including: Supporting Women in Achieving Greatness, and Diversity, Equity and Inclusion committee in the Department of Internal Medicine at UTSW.

Briefly, Puneeth Iyengar joined the UT Southwestern Medical Center in Dallas, TX USA in the summer of 2010 and is currently an Assistant Professor of Radiation Oncology, with a professional emphasis on treating lung cancer patients. He is co-leader of the Thoracic Oncology Program in the Harold Simmons Comprehensive Cancer Center, leader of the Lung Radiation Oncology Team, Director of Clinical Research for the Department of Radiation Oncology, and institutional representative to NRG from UT Southwestern. His clinical focus is on studying local therapy for oligometastatic NSCLC. He has published significantly in this area, in top tier journals including JCO, JAMA Oncology, Lancet Oncology, among others. He is overall PI of the international trial NRG LU 002, a randomized phase III study assessing local therapy in the setting of immunotherapy and oligometastatic NSCLC. As a physician scientist, Dr. Iyengar runs an independent laboratory with a focus on studying the complex crosstalk between inflammatory states, cachexia, and lung cancer progression and therapeutic resistance. His research program has been funded by organizations including the National Lung Cancer Partnership, Lung Cancer Research Foundation, and Radiological Society of North America. He has also received a President’s Council Distinguished Researcher Award from UT Southwestern Medical Center at Dallas as well as a Sidney Kimmel Research Foundation Award over the last few years. Finally, he received an American Cancer Society Independent Investigator Research Scholar Award. He received his undergraduate degree from MIT, MD and PhD degrees from the Albert Einstein College of Medicine in New York City, and radiation oncology residency training from MD Anderson Cancer Center in Houston. In addition, he is Board Certified in Radiation Oncology and have been granted medical licensure to practice in Texas.

Jonathan Dowell, M.D., is a Professor in the  at UT Southwestern, and a member of the . He also serves as Chief of Hematology/Oncology at the Dallas VA Medical Center.
Dr. Dowell specializes primarily in thoracic malignancies, including non-small cell and small cell lung cancers, mesothelioma, and thymoma.
Dr. Dowell earned his bachelor’s degree in neuroscience from Amherst College in Massachusetts, where he graduated magna cum laude. He received his medical degree from the University of Chicago’s Pritzker School of Medicine and completed internal medicine residency training at UT Southwestern Medical Center. He then completed advanced training through a fellowship in hematology and oncology at Vanderbilt University in Nashville.
Certified by the American Board of Internal Medicine in hematology and in oncology, Dr, Dowell joined the UT Southwestern faculty in 1996.
Dr. Dowell’s research interests include thoracic malignancies. His investigations have resulted in 40 publications in peer-reviewed journals and contributions to more than 50 book chapters, reviews, editorials, and case reports. Additionally, he has presented his findings at scientific conferences throughout the United States and internationally.
At UT Southwestern, Dr. Dowell chairs the Simmons Cancer Center Data and Safety Monitoring Committee and co-chairs the Dallas VA Transfusion Utilization Committee and the Veterans Integrated Service Network 17 Hematology/Oncology Work Group.
Dr. Dowell is active in several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, the Texas Medical Association, and the Dallas County Medical Society.